These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 18518787

  • 1. Morphine sulfate extended-release capsules for the treatment of chronic, moderate-to-severe pain.
    Nicholson B.
    Expert Opin Pharmacother; 2008 Jun; 9(9):1585-94. PubMed ID: 18518787
    [Abstract] [Full Text] [Related]

  • 2. Factors affecting dosing regimens of morphine sulfate extended-release (KADIAN) capsules.
    Weil AJ, Nicholson B, Sasaki J.
    J Opioid Manag; 2009 Jun; 5(1):39-45. PubMed ID: 19344047
    [Abstract] [Full Text] [Related]

  • 3. KADIAN (morphine sulfate extended-release) capsules for treatment of chronic, moderate-to-severe, nonmalignant pain.
    Ross EL, Hahn K.
    Int J Clin Pract; 2008 Mar; 62(3):471-9. PubMed ID: 18261077
    [Abstract] [Full Text] [Related]

  • 4. Effect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of KADIAN (morphine sulfate extended-release) capsules.
    Johnson F, Wagner G, Sun S, Stauffer J.
    J Pain; 2008 Apr; 9(4):330-6. PubMed ID: 18201934
    [Abstract] [Full Text] [Related]

  • 5. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
    Johnson FK, Ciric S, Boudriau S, Kisicki JC, Stauffer J.
    Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
    [Abstract] [Full Text] [Related]

  • 6. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain.
    Portenoy RK, Sciberras A, Eliot L, Loewen G, Butler J, Devane J.
    J Pain Symptom Manage; 2002 Apr; 23(4):292-300. PubMed ID: 11997198
    [Abstract] [Full Text] [Related]

  • 7. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
    Katz N, Sun S, Johnson F, Stauffer J.
    J Pain; 2010 Apr; 11(4):303-11. PubMed ID: 19944650
    [Abstract] [Full Text] [Related]

  • 8. A randomized, open-label study of once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: the extension phase of the ACTION trial.
    Rauck RL, Bookbinder SA, Bunker TR, Alftine CD, Ghalie R, Negro-Vilar A, de Jong E, Gershon S.
    J Opioid Manag; 2006 Apr; 2(6):325-8, 331-3. PubMed ID: 17326594
    [Abstract] [Full Text] [Related]

  • 9. Administration of morphine sulfate extended-release capsules via gastrostomy: dissolution study and case reports.
    Shaiova L, Mori M, Anderson K, Loewen G, Ghalie R, Homel P, Portenoy R.
    J Palliat Med; 2007 Oct; 10(5):1063-7. PubMed ID: 17985962
    [Abstract] [Full Text] [Related]

  • 10. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain.
    Webster LR, Brewer R, Wang C, Sekora D, Johnson FK, Morris D, Stauffer J.
    J Pain Symptom Manage; 2010 Nov; 40(5):734-46. PubMed ID: 21075272
    [Abstract] [Full Text] [Related]

  • 11. The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain.
    Rauck RL, Bookbinder SA, Bunker TR, Alftine CD, Ghalie R, Negro-Vilar A, de Jong E, Gershon S.
    J Opioid Manag; 2006 Nov; 2(3):155-66. PubMed ID: 17319449
    [Abstract] [Full Text] [Related]

  • 12. Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing.
    Smith HS.
    Expert Opin Pharmacother; 2011 May; 12(7):1111-25. PubMed ID: 21470065
    [Abstract] [Full Text] [Related]

  • 13. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain.
    Nicholson B, Ross E, Sasaki J, Weil A.
    Curr Med Res Opin; 2006 Aug; 22(8):1503-14. PubMed ID: 16870075
    [Abstract] [Full Text] [Related]

  • 14. Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules.
    Nicholson B, Ross E, Weil A, Sasaki J, Sacks G.
    Curr Med Res Opin; 2006 Mar; 22(3):539-50. PubMed ID: 16574037
    [Abstract] [Full Text] [Related]

  • 15. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.
    Gourlay GK.
    Clin Pharmacokinet; 1998 Sep; 35(3):173-90. PubMed ID: 9784932
    [Abstract] [Full Text] [Related]

  • 16. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
    Johnson FK, Ciric S, Boudriau S, Kisicki J, Stauffer J.
    J Clin Pharmacol; 2012 May; 52(5):747-56. PubMed ID: 21593282
    [Abstract] [Full Text] [Related]

  • 17. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain.
    Katz N, Hale M, Morris D, Stauffer J.
    Postgrad Med; 2010 Jul; 122(4):112-28. PubMed ID: 20675975
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
    Fleming AB, Carlson DR, Varanasi RK, Grima M, Mayock SP, Saim S, Kopecky EA.
    Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
    Setnik B, Roland CL, Goli V, Sommerville K, Webster L.
    J Opioid Manag; 2013 Mar; 9(2):139-50. PubMed ID: 23709323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.